Mohamad Mohty
Professor of Hematology and past-president of the European society for Blood and Marrrow Transplantation (EBMT)
Last synced from Twitter 87d ago
Amyloidosis classification and epidemiology
Joan Blade, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses amyloidosis classification and epidemiology. Specifically highlighted is AL amyloidosis,...
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children | Blood Advances | American Society of Hematology
Key Points. Cytokine profiling can distinguish cytokine release syndrome after chimeric antigen receptor T-cell (CAR-T) therapy from sepsis.Cytokine profiling
Title not found
1
Mohamad Mohty
You can register at register.gotowebinar.com/register/45915… pic.twitter.com/12gB67Teti
90d
Mohamad Mohty
@Rfonsi1 @anish_koka @TheIACH
89d
Mohamad Mohty
@szusmani @Rfonsi1 @anish_koka @TheIACH
89d
Should all patients with MM receive maintenance therapy after transplantation?
During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Graham Jackson, Newcastle University, Newcastle upon Tyne, UK, about maintenance therapy after transplantation. We asked, Should all patients...
Treating AML patients who are not eligible for intensive chemotherapy
Thomas Prebet, MD, Yale School of Medicine, New Haven, CT, discusses the challenge of treating acute myeloid leukemia (AML) patients...
Transplant for older leukemia patients
Didier Blaise, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses transplant therapy for older patients. For many years older patients have...
Antibody-based therapy to treat AML: radioimmunoconjugates
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-based therapy in acute...
COMy 2020 highlights: smoldering myeloma, MRD and immunotherapy
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of the topics discussed during the COMy 2020...
The future of CAR T-cells and bispecific antibodies to treat myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the future of CAR T-cells and bispecific antibodies...
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience
(2020). Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience. Leukemia & Lymphoma. Ahead of Print.
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
There is limited information on the characteristics, prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals within the...
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous...
Immune-based therapies in the management of multiple myeloma
Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two...
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
Autologous stem cell transplantation (ASCT) is an important treatment modality in multiple myeloma (MM). However, relapse following ASCT is considered almost inevitable. This study aimed to characterize exceptional responders to ASCT, defined as...
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological malignancy, characterized by plasma cell bone marrow infiltration and end-organ involvement. Smoldering MM (SMM) is an intermediate clinical entity between MGUS and MM, with a risk of...
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk...